

- Disopyramide
adverse effects of, 1480t
for arrhythmias, 1479, 1480t, 1489, 1498
dosage of, 1480t
pharmacology of, 1480t
therapeutic monitoring of, 2764t
- Disorders of sex development (DSDs), **2349**
classification of, 2350t
global considerations in, 2357
sex chromosome disorders. *See* Sex chromosome disorders
46,XX disorders. *See* 46,XX disorders of sex development
46,XY disorders. *See* 46,XY disorders of sex development
- Disposable soma theory of aging, 94e-2
- Disseminated intravascular coagulation (DIC), **736**
chronic, 738
clinical features of, 737
diagnosis of, 737
etiology of, 737, 737t
in filovirus infections, 1327
in leptospirosis, 1142
pathophysiology of, 737, 737f
in pregnancy, 49
in sepsis/septic shock, 1754, 1757
skin manifestations of, 368, 782
treatment of, 738
- Distal convoluted tubule, 332e-4f, 332e-7t, 332e-8
- Distal myopathies, 462e-12, 462e-13t
- Disulfiram
adverse effects of, 203, 2687t
in alcoholism management, 2728
drug interactions of, 246e-5t
- DITRA (deficiency of the IL-36 receptor antagonist), 2215
- Diuresis
for hypercalcemia, 2480t, 2481
postobstructive, 1874
water, 2275, 2276f
- Diuretics
abuse of, 307
action of, 297
adverse effects of
acid-base disorders, 322
gout, 2218t
hypokalemia, 305–306, 307
hyponatremia, 299
hypovolemia, 297
renal, 291
urinary incontinence, 81
xerostomia, 241
- aldosterone-renin ratio effects of, 2320t
for ascites, 288
for chronic venous disease, 1652
for heart failure, 1508, 1509f, 1510t, 1512–1513, 1608
for hyperkalemia, 312
for hypertension, 1623, 1624t
for Ménière's disease, 219
for pulmonary edema, 1763
for vertigo, 151t
- Divalent metal transporter, 626
- Divers Alert Network, 2741
- Diversion colitis, 1957
- Diversity, 86e-1t
- Diverticular disease, **1971**
anatomy of, 1971
bleeding in, 277, 1971
clinical features of, 1971–1972, 1972t
diagnosis of, 1891, 1893f, 1971–1972
epidemiology of, 1971
esophageal, 1903, 1903f
incidence of, 1971
jejunal, 1939f
pathophysiology of, 1971, 1971f
recurrent, 1973
treatment of, 346e-1v, 1893f, 1972–1973, 1973f, 1973t
Zenker's, 256, 259, 1903, 1903f
- Diverticulitis
clinical features of, 106t, 267, 1971–1972, 1972t
diagnosis of, 1971–1972
Hinchey classification of, 1972, 1972f
vs. IBD, 1957
- Diving medicine, **477e-6**
barotrauma, 477e-6–7
breathing equipment, 477e-6
decompression sickness, 477e-4t, 477e-7–8, 477e-7t
suitability evaluation, 477e-6
- Dix-Hallpike maneuver, 149
- Dizziness, **148**. *See also* Vertigo
approach to the patient, 148–149
diagnostic testing in, 149
etiology of, 148
physical examination in, 149
psychosomatic, 151
- DJ-1, 444e-9
- DKA. *See* Diabetic ketoacidosis (DKA)
- DKC1 gene mutations, 664
- DKK-1, 2143
- DL_{CO} (diffusion capacity of the lung for carbon monoxide), 306e-5f, 306e-6, 1710
- DLT (dose-limiting toxicity), 103e-5
- DM. *See* Diabetes mellitus (DM)
- DMAA (1,3-dimethylamylamine), 14e-3
- DMARDs (disease-modifying antirheumatic drugs), 2145–2147, 2146–2147t
- DMD gene mutations, 434, 436, 1555t
- DMF (dimethyl fumarate), 2669t, 2670, 2671
- DMSA (succimer), 472e-2–3t
- DNA
demethylation of, 102e-8
epigenetic modifications of, 429–431, 431f
human, 425
methylation of, 101e-4, 429–430, 431f, 432f
mitochondrial. *See* Mitochondrial DNA (mtDNA)
repetitive, 427
replication of, 427, 428f
structure of, 426–427, 427f
unstable sequences, 434
- DNA-dependent nucleoside-stimulated ATPase, 372e-24t
- DNA gyrase, 932
- DNA-interactive agents, 103e-8, 103e-9t, 103e-12. *See also specific drugs*
- DNA methyltransferase inhibitors, 103e-20
- DNA repair, 375e-1–2, 386, 434, 2109
- DNase aerosols, 1699
- DNA sequencing
in genetic testing, 427, 447. *See also* Genetic testing
multiplex, 86e-2, 86e-3f, 447
of stem cells, 455
- DNA topoisomerase II, 372e-25t
- DNA virus(es), 214e-2t, 214e-3f, 214e-4–5. *See also specific viruses*
- DNMT3A gene mutations, 680, 680t
- Dobrava-Belgrade virus, 1307t
- Dobutamine
for cardiogenic shock, 1761, 1761f
for heart failure, 1509–1510, 1510t
for pulmonary edema, 1761f, 1763
for sepsis/septic shock, 1757
for shock, 1751
in stress testing, 270e-3
- DOC (deoxycorticosterone), 2309f, 2313, 2319
- Docetaxel
action of, 103e-14–15
adverse effects of, 103e-12t, 103e-15, 1797, 2218t, 2686t
for breast cancer, 529
drug interactions of, 246e-3t
for gastric cancer, 535
for head and neck cancer, 505
for lung cancer, 520, 520t, 521
for melanoma, 499
premedication for, 103e-12t, 103e-15
for prostate cancer, 586
for soft tissue sarcoma, 119e-2
- DOCK8 deficiency, 420t, 423
- Docosanol, 215e-3t
- Docusate, 61, 62t
- Dofetilide
action of, 273e-6t
adverse effects of, 1480t, 1489, 1498
for arrhythmias, 1480t
for atrial fibrillation, 1489
for atrial flutter, 1485
dosage in kidney disease, 37
dosage monitoring, 36
dosage of, 1480t
drug interactions of, 43, 246e-3t
pharmacology of, 1480t
for ventricular arrhythmias, 1498
- Dog(s)
bite-wounds, **167e-1, 782**
antibiotic prophylaxis for, 167e-3
approach to the patient, 167e-2
cellulitis in, 830
infections from, 167e-1, 183e-3
microbiology of, 167e-1
rabies prophylaxis for, 167e-3
treatment of, 167e-2–3, 167e-3t, 832t
- filarial infections, 1423
- fleas, 2750
- tapeworms, 1435
- ticks, 1154
- Döhle bodies, 81e-2, 81e-7f, 415, 415f
- Dolasetron, 62, 103e-25
- “Doll's eyes,” 1775
- Dolor, 414f, 1753
- Dolutegravir, 1275t, 1281
- Domains of life, 86e-1t
- Domestic abuse/violence
human bite-wounds in, 167e-2
incidence of, 6e-5, 2723
lifetime cumulative risk of, 27t
mandated reporting of, 17e-1
screening for, 29t, 2722–2723
- Domoic acid intoxication (amnesic shellfish poisoning), 2547–2548, 2743
- Domperidone
adverse effects of, 261–262
for gastroparesis, 260, 260t, 2164, 2641
for migraine, 2591
for nausea, 109
- Donath-Landsteiner antibodies, 138e-2, 659
- Donepezil
for AD, 176, 217, 2601
for cognitive problems in MS, 2672
for opioid-induced drowsiness, 61
for Parkinson's disease dementia, 2617
- Dong quai, 404t
- Do-not-resuscitate (DNR) orders, 67
- Donovan bodies, 198e-1, 198e-1f
- Donovanosis, **198e-1**
clinical features of, 198e-1, 198e-1f, 880t
diagnosis of, 198e-1–2, 198e-1f
differential diagnosis of, 198e-2
epidemiology of, 198e-1, 879
etiology of, 198e-1
global considerations in, 198e-1
prevention and control of, 198e-2
treatment of, 198e-2, 198e-2t
- L-Dopa. *See* Levodopa
- Dopamine
action of, 444e-3t
for cardiogenic shock, 1761, 1761f
in cardiovascular regulation, 1613
clinical aspects of, 444e-3t
for hypothermia, 478e-3
in migraine, 2588
for pulmonary edema, 1763
reference values for, 2759t
for shock, 1750, 1751
structure of, 444e-3t
- Dopamine agonists
for acromegaly, 2271
adverse effects of, 192, 2268, 2615
for ovulatory dysfunction, 2389
for PD, 2615, 2616t
for prolactinoma, 2267–2268
for restless legs syndrome, 192